| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Tryptamine (0–60 μM; 24, 48, and 72 h) inhibits MCF-7 cell colony growth and proliferation [1]. EMT-associated E-calcium is restored by tryptophan (6.25–25 μM; 48 h; MCF-7 cells). With an IC50 value of 0.6 μM [Mucin, MMP-2, and Snail], tryptamine (0-30 μM; 15 min; MCF-7 cells) decreases leukotriene (LT)-formation in human neutrophils.
|
|---|---|
| ln Vivo |
Tryptamine (25-100 mg/kg; intraperitoneal; daily for 13 days; female Bal b/c mice with 4T1 xenografts) suppresses the formation of tumors and modifies IL-2, IL-6, IL-10, and IL-Tryptophan (10 mg/kg; powder; Vehicle Wistar Han Stent) to produce LTB4 in vivo [2].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: MCF-7 cells Tested Concentrations: 0-60 μM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: The inhibition rate of MCF-7 cells increased in a dose- and time-dependent manner. 2]. Way. Western Blot Analysis[1] Cell Types: MCF-7 Cell Tested Concentrations: 6.25, 12.5 and 25 μM Incubation Duration: 48 hrs (hours) Experimental Results: E-cadherin protein levels increased, MMP-2 and Snail protein expression levels were Dramatically up-regulated TGF-β1 induction of MCF-7 cells. |
| Animal Protocol |
Animal/Disease Models: α levels in female Bal b/c mice 12 and TNF-tumor-bearing mice [1]. 4T1 Xenograft[1]
Doses: 25, 50 and 100 mg/kg Route of Administration: po (oral gavage); one time/day for 13 days Experimental Results: Inhibition of tumor growth in a dose-dependent manner. Animal/Disease Models: Male Wistar Han rat (220-230 g) [2] Doses: 10 mg/kg Route of Administration: Oral; primary Experimental Results: LTB4 pleural levels were diminished by 46%. diminished PGE2 levels (42% reduction), exudate volume (80% reduction), and infiltrating cell number (41% reduction). |
| References |
[1]. Zeng Q, et, al. Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment. Acta Pharm. 2021 Jun 1;71(2):245-266.
[2]. Pergola C, et, al. On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo. Br J Pharmacol. 2012 Feb;165(3):765-76. |
| Molecular Formula |
C15H8N2O2
|
|---|---|
| Molecular Weight |
248.2362
|
| Exact Mass |
248.06
|
| Elemental Analysis |
C, 72.58; H, 3.25; N, 11.29; O, 12.89
|
| CAS # |
13220-57-0
|
| Appearance |
Solid powder
|
| SMILES |
C1=CC=C2C(=C1)C(=O)N3C4=CC=CC=C4C(=O)C3=N2
|
| InChi Key |
VQQVWGVXDIPORV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H8N2O2/c18-13-10-6-2-4-8-12(10)17-14(13)16-11-7-3-1-5-9(11)15(17)19/h1-8H
|
| Chemical Name |
indolo[2,1-b]quinazoline-6,12-dione
|
| Synonyms |
Tryptanthrin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.14 mg/mL (~28.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.71 mg/mL (2.86 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.67 mg/mL (2.70 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0284 mL | 20.1418 mL | 40.2836 mL | |
| 5 mM | 0.8057 mL | 4.0284 mL | 8.0567 mL | |
| 10 mM | 0.4028 mL | 2.0142 mL | 4.0284 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
